Cue Biopharma Inc. hopes to achieve perfect harmony with LG Chem Life Sciences, the life sciences division of Korean giant LG Chem Ltd. (LGC), in a multitarget collaboration to develop its Immuno-STAT (Selective Targeting and Alteration of T cells) immuno-oncology (I-O) biologics. The deal provides LG Chem with rights in Asia to develop and commercialize Cue's lead candidate, CUE-101, and Immuno-STAT biologics that target T cells against two additional cancer antigens.